Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDIGEN VACCINE BIOLOGICS CORPORATION

(6547)
  Report
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Medigen Vaccine Biologics : Taiwan approves production of Medigen's COVID-19 vaccine candidate

07/19/2021 | 02:12am EDT

TAIPEI, July 19 (Reuters) - Taiwan's government on Monday approved the production of Medigen Vaccine Biologics Corp's COVID-19 vaccine candidate.

The health ministry said in clinical trials in Taiwan the antibodies created by Medigen's vaccine candidate have been proven to be "no worse than" those created by AstraZeneca PLC vaccines, and that there were no major safety concerns. (Reporting by Ben Blanchard and Yimou Lee; Editing by Christopher Cushing)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 6.04% 8550 Delayed Quote.10.09%
MEDIGEN VACCINE BIOLOGICS CORPORATION 0.70% 286 End-of-day quote.177.67%
All news about MEDIGEN VACCINE BIOLOGICS CORPORATION
09/07Vaccine makers should supply shots for trials to help spur sector -CEPI
RE
09/01Helped by TSMC and Foxconn, BioNTech vaccines finally reach Taiwan
RE
09/01Helped by tech giants, BioNTech vaccines finally reach Taiwan
RE
08/30Foxconn founder asks BioNTech to reserve 30 million more vaccines for Taiwan
RE
08/25REFILE-Taiwan to get BioNTech shots early as China delays approval-source
RE
08/23DYNAVAX TECHNOLOGIES : Medigen Vaccine Biologics Launch COVID-19 Vaccine in Taiw..
MT
08/22MEDIGEN VACCINE BIOLOGICS : Taiwan leader gets local COVID-19 vaccine as rollout..
AQ
08/16Taiwan rejects COVID vaccine candidate, president to get domestic shot
RE
08/16Taiwan denies approval for UBI's COVID-19 vaccine candidate
RE
08/12Medigen Vaccine Biologics Corporation Reports Earnings Results for the Second..
CI
More news
Financials
Sales 2020 11,5 M 0,41 M 0,41 M
Net income 2020 -674 M -24,3 M -24,3 M
Net cash 2020 1 545 M 55,6 M 55,6 M
P/E ratio 2020 -28,6x
Yield 2020 -
Capitalization 60 773 M 2 183 M 2 189 M
EV / Sales 2019 4 269x
EV / Sales 2020 1 755x
Nbr of Employees 103
Free-Float 65,3%
Chart MEDIGEN VACCINE BIOLOGICS CORPORATION
Duration : Period :
Medigen Vaccine Biologics Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDIGEN VACCINE BIOLOGICS CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Managers and Directors
Tsan Chien Chen General Manager & Director
Yu Ping Yang Head-Finance & Accounting
Shih Chung Chang Chairman
Yi Hsu Huang Chief Technology Officer & Deputy General Manager
Ming Cheng Chang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MEDIGEN VACCINE BIOLOGICS CORPORATION177.67%2 187
CSL LIMITED8.56%102 521
WUXI BIOLOGICS (CAYMAN) INC.18.00%67 077
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 329
BIOGEN INC.22.60%44 738
ALEXION PHARMACEUTICALS, INC.0.00%40 336